Geron Corporation

Geron to Participate at Upcoming Investor Conferences in April

Retrieved on: 
Wednesday, April 3, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Geron Corporation, Webcast, Corporation, Fireside, Event, Fireside chats

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to present at the following virtual investor conferences:

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to present at the following virtual investor conferences:
    Wednesday, April 10th at 10:15 a.m.
  • ET (Fireside Chat)
    Wednesday, April 17th at 11:30 a.m.
  • ET (Corporate Presentation)
    A webcast of each fireside chat and corporate presentation will be available through the Investor Relations section of the Company’s website under Events .
  • An archive of the webcast will be available on the Company’s website for 30 days.

Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Retrieved on: 
Tuesday, March 19, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Hospitals, Clinical Trials, Montgomery Street, Form, Telephone, Corporation, Sale, Attention, Syndrome, Security (finance), Lexington Avenue, Suite, Form S-3, Prospectus, OrbiMed, Geron Corporation

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of an underwritten offering consisting of 41,999,998 shares of its common stock at a price of $3.00 per share and pre-funded warrants to purchase 8,002,668 shares of its common stock.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of an underwritten offering consisting of 41,999,998 shares of its common stock at a price of $3.00 per share and pre-funded warrants to purchase 8,002,668 shares of its common stock.
  • All of the securities in the offering are to be sold by Geron.
  • The offering is expected to close on or about March 21, 2024, subject to the satisfaction of customary closing conditions.
  • The gross proceeds to Geron from this underwritten offering, before deducting the underwriting discount and other estimated offering expenses, are expected to be approximately $150.0 million.

Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS

Retrieved on: 
Thursday, March 14, 2024
Research, Hospitals, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Bone marrow, Patient, Transfusion-dependent anemia, Corporation, Imetelstat, ODAC, Anemia, Geron Corporation, MDS, Food, Medicine, Pharmaceutical industry

“We are pleased with the Committee’s decision to recognize the positive clinical benefit/risk profile of imetelstat for the treatment of transfusion-dependent anemia in adult patients with lower-risk MDS.

Key Points: 
  • “We are pleased with the Committee’s decision to recognize the positive clinical benefit/risk profile of imetelstat for the treatment of transfusion-dependent anemia in adult patients with lower-risk MDS.
  • Additionally, a sustained increase in mean hemoglobin levels in imetelstat-treated patients was observed over time compared to placebo patients.
  • The ODAC provides the FDA with independent opinions and recommendations from outside medical experts, patients and caregivers, though the recommendations are not binding.
  • Geron plans to commercially launch imetelstat in the U.S. upon potential FDA approval.

Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, February 28, 2024
Biotechnology, General Health, Pharmaceutical, Health, Janus, Hercules, BAT, European Commission, EMA, Marketing, Research, New Drug Application, Anemia, Transfusion-dependent anemia, Syndrome, MAA, MF, FDA, Geron Corporation, Imetelstat, Exercise, PDUFA, Loan, Risk, Primary myelofibrosis, Society, MDS, Civil service commission, JAK, History, European Medicines Agency, Webcast, Register, SVB, Patient, Federal, Clinical trial, Corporation, NDA, Depreciation

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported business highlights and financial results for the fourth quarter and full year 2023.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported business highlights and financial results for the fourth quarter and full year 2023.
  • The FDA assigned a Prescription Drug User Fee Act (PDUFA) action date of June 16, 2024 to the NDA.
  • In September 2023, the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for imetelstat in the same proposed indication as the NDA.
  • Geron will host a conference call at 8:00 am ET on Wednesday, February 28, 2024, to discuss business updates and fourth quarter and full year 2023 financial results.

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, February 22, 2024
Biotechnology, Pharmaceutical, Health, Geron Corporation, Corporation, Employment

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 397,010 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 397,010 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
  • The stock options were granted on February 21, 2024, at an exercise price of $1.93 per share, which is equal to the closing price of Geron common stock on the date of grant.
  • Stock options representing an aggregate of 8,570 shares have a 10- year term and vest in full upon achievement of a certain regulatory milestone, subject to continued employment with Geron through the applicable vesting date.
  • All of the stock options were granted as material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of the stock option agreements covering the grants and Geron’s 2018 Inducement Award Plan, which was adopted December 14, 2018, and provides for the granting of stock options to new employees.

Geron to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024

Retrieved on: 
Wednesday, February 14, 2024
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Other Science, Research, Hospitals, Science, Clinical Trials, Geron Corporation, Corporation, Webcast

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its fourth quarter and full-year 2023 financial results and business highlights before the market opens on Wednesday, February 28, 2024 via press release, which will be available on the Company’s website at www.geron.com/investors .

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its fourth quarter and full-year 2023 financial results and business highlights before the market opens on Wednesday, February 28, 2024 via press release, which will be available on the Company’s website at www.geron.com/investors .
  • Geron will host a conference call to discuss the financial results as well as business highlights at 8:00 a.m.
  • A live webcast of the conference call and related presentation will be available on the Company’s website at www.geron.com/investors/events .
  • An archive of the webcast will be available on the Company’s website for 30 days.

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, January 18, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Corporation, Geron Corporation, Employment

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 895,930 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 895,930 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
  • The stock options were granted on January 17, 2024, at an exercise price of $1.92 per share, which is equal to the closing price of Geron common stock on the date of grant.
  • Stock options representing an aggregate of 22,930 shares have a 10-year term and vest in full upon achievement of a certain regulatory milestone, subject to continued employment with Geron through the applicable vesting date.
  • All of the stock options were granted as material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of the stock option agreements covering the grants and Geron’s 2018 Inducement Award Plan, which was adopted December 14, 2018, and provides for the granting of stock options to new employees.

Geron to Participate in the B. Riley Securities Virtual Oncology Conference

Retrieved on: 
Friday, January 12, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Corporation, Geron Corporation, Conference, Webcast

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to participate in a fireside chat at the B. Riley Securities Virtual Oncology Conference on Thursday, January 18th, 2024, at 10:30am ET.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to participate in a fireside chat at the B. Riley Securities Virtual Oncology Conference on Thursday, January 18th, 2024, at 10:30am ET.
  • A webcast of the presentation will be available through the Investors and Media section of Geron’s website under Events following the presentation.
  • The webcast will be archived and available for replay for a period of 30 days.

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, December 21, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Corporation, Employment, Geron Corporation

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 417,490 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 417,490 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
  • The stock options were granted on December 20, 2023 at an exercise price of $2.16 per share, which is equal to the closing price of Geron common stock on the date of grant.
  • Stock options representing an aggregate of 12,490 shares have a 10-year term and vest in full upon achievement of a certain regulatory milestone, subject to continued employment with Geron through the applicable vesting date.
  • All of the stock options were granted as material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of the stock option agreements covering the grants and Geron’s 2018 Inducement Award Plan, which was adopted December 14, 2018 and provides for the granting of stock options to new employees.

Geron Announces IMerge Phase 3 Presentations at ASH Highlighting Significant Durability of Transfusion Independence and Breadth of Effect Across MDS Subgroups with Imetelstat in Lower Risk MDS

Retrieved on: 
Monday, December 11, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Yale Cancer Center, Associate, International Prognostic Scoring System, Quality, IPSS, VAF, ASH, Acute myeloid leukemia, Cytopenia, Risk, Pros, Corporation, Yale school, Fatigue, Patient, Thrombocytopenia, Research, Periodic breathing, Imetelstat, Quality of life, Internal medicine, MDS, Neutropenia, MBBS, Yale School of Medicine, Bleeding, Survival, Pain, AML, Geron Corporation, Society, Iron overload, Mutation, RBC, Pharmaceutical industry, Dietary supplement, Lancet, Geron, SF3B1, Blood, Medicine, Hematology

The results showed that imetelstat consistently had higher RBC-TI response rates than placebo across these different risk subgroups.

Key Points: 
  • The results showed that imetelstat consistently had higher RBC-TI response rates than placebo across these different risk subgroups.
  • Overall, durable 24-week and 1-year RBC-TI responses were observed with imetelstat in all lower- and higher-risk subgroups.
  • This analysis suggests clinical benefit of imetelstat across different molecularly defined subgroups and independent of the underlying molecular mutation pattern.
  • This analysis indicates that achievement of RBC-TI was associated with improved survival, suggesting that transfusion dependence is a modifiable predictor of clinical outcomes in lower risk MDS.